Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373542 · ClinicalTrials.gov registry record · Phase 4
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
A Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT00373542: Completed Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), sponsored by GlaxoSmithKline.
NCT00373542 is a Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS) that has completed, run by GlaxoSmithKline. The registered enrollment target is 39 participants, below the 94-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00373542, a Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.
Conditions Studied
Interventions
- DRUG ropinirole CR-RLS
Study Locations (20)
Florida
- GSK Investigational Site - Brandon
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - St. Petersburg
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Austell
- GSK Investigational Site - Macon
Alabama
- GSK Investigational Site - Jasper
- GSK Investigational Site - Tuscaloosa
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - San Diego
Colorado
- GSK Investigational Site - Greenwood
- GSK Investigational Site - Wheat Ridge
Illinois
- GSK Investigational Site - Elk Grove Village
- GSK Investigational Site - Normal
Kansas
- GSK Investigational Site - Lenexa
- GSK Investigational Site - Topeka
Arizona
- GSK Investigational Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
What the finished NCT00373542 record still lists
NCT00373542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 94-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ropinirole CR-RLS is the first listed.
NCT00373542 names 20 study sites across 11 states, led by Florida, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT00373542 about?
NCT00373542 is a clinical study titled "12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome". The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.
What is the current status of trial NCT00373542?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2006-10. Estimated completion is 2007-06.
What conditions does trial NCT00373542 study?
This clinical trial studies the following conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS).
What interventions are being tested in trial NCT00373542?
The interventions under investigation include: ropinirole CR-RLS (DRUG).
Who is sponsoring clinical trial NCT00373542?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373542 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00373542's enrollment target sits among peer trials
39 9th of 14 higher than 6 of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia